BR9908325A - 6 9-dissubstituìdo 2-[trans-4(4-aminociclohexil)amino]purinas - Google Patents

6 9-dissubstituìdo 2-[trans-4(4-aminociclohexil)amino]purinas

Info

Publication number
BR9908325A
BR9908325A BR9908325-6A BR9908325A BR9908325A BR 9908325 A BR9908325 A BR 9908325A BR 9908325 A BR9908325 A BR 9908325A BR 9908325 A BR9908325 A BR 9908325A
Authority
BR
Brazil
Prior art keywords
present
provides
group
alkyl
formula
Prior art date
Application number
BR9908325-6A
Other languages
English (en)
Inventor
Jennifer A Dumont
Alan J Bitonti
David R Borcherding
Norton P Peet
Randall H Munson
Patrick W K Shum
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BR9908325A publication Critical patent/BR9908325A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"6,9-DISSUBSTITUìDO 2-[TRANS-4(4-AMINOCICLOHEXIL)AMINO]PURINAS"<D>. A presente invenção fornece novos compostos de fórmula (I) na qual R é selecionado do grupo consistindo em R2, R2NH-, ou H~ 2~N-R~ 3- onde R2 é selecionado do grupo consistindo em C~ 1~ - C~ 8~ alquila e fórmula (II), na qual Z é selecionado do grupo consistindo em fenila, heterociclo e cicloalquila, cada R4 é independentemente hidrogênio ou C~ 1~ - C~ 4~ alquila, e n é um número inteiro de 1 a 8; onde cada C~ 1~ - C~ 8~ alquila e Z é opcionalmente substituído com 1 a 3 substituintes, que podem ser os mesmos ou diferentes, selecionados do grupo consistindo em Hal, OH, e C~ 1~ - C~ 4~ alquila; R3 é C~ 1~ - C~ 8~ alquileno; e R1 é selecionado do grupo consistindo em ciclopentila e isopropila, e os sais farmaceuticamente aceitáveis, isómeros óticos, e hidratos dos mesmos. Em adição, a presente invenção fornece um método de inibição da progressão do ciclocelular. Mais especificamente, a presente invenção provê um método de inibição das cinases dependentes de ciclina, particularmente cdk-2. A presente invenção também fornece um método de impedir a apoptose em células neuronais e um método de inibição do desenvolvimento de neoplasmas. Além disso, a presente invenção fornece uma composição compreendendo uma quantidade testável de um composto de fórmula (I) em mistura ou de outra maneira em associação com um carreador inerte. A presente invenção também fornece uma composição farmacêutica compreendendo uma quantidade inibidora eficaz de um composto de fórmula (I) em mistura ou de outra maneira em associação com um ou mais carreadores ou excipientes farmaceuticamente aceitáveis.
BR9908325-6A 1998-02-26 1999-02-18 6 9-dissubstituìdo 2-[trans-4(4-aminociclohexil)amino]purinas BR9908325A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3238198A 1998-02-26 1998-02-26
PCT/US1999/003451 WO1999043676A2 (en) 1998-02-26 1999-02-18 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines

Publications (1)

Publication Number Publication Date
BR9908325A true BR9908325A (pt) 2000-11-07

Family

ID=21864658

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908325-6A BR9908325A (pt) 1998-02-26 1999-02-18 6 9-dissubstituìdo 2-[trans-4(4-aminociclohexil)amino]purinas

Country Status (31)

Country Link
EP (1) EP1056745B1 (pt)
JP (1) JP2002504553A (pt)
KR (1) KR100568658B1 (pt)
CN (1) CN1128149C (pt)
AP (1) AP1258A (pt)
AR (1) AR019822A1 (pt)
AT (1) ATE269332T1 (pt)
AU (1) AU748178B2 (pt)
BR (1) BR9908325A (pt)
CA (1) CA2320448C (pt)
CZ (1) CZ291604B6 (pt)
DE (1) DE69918062T2 (pt)
DK (1) DK1056745T3 (pt)
EE (1) EE04315B1 (pt)
ES (1) ES2219038T3 (pt)
HK (1) HK1030948A1 (pt)
HU (1) HUP0100931A3 (pt)
IL (2) IL138044A0 (pt)
NO (1) NO20004281L (pt)
NZ (1) NZ506234A (pt)
OA (1) OA11480A (pt)
PL (1) PL344021A1 (pt)
PT (1) PT1056745E (pt)
RU (1) RU2191777C2 (pt)
SI (1) SI1056745T1 (pt)
SK (1) SK12912000A3 (pt)
TR (1) TR200002482T2 (pt)
TW (1) TW541308B (pt)
UA (1) UA62996C2 (pt)
WO (1) WO1999043676A2 (pt)
ZA (1) ZA991548B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
AU2001277285A1 (en) 2000-08-09 2002-02-18 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
EP1309563B1 (en) 2000-08-18 2005-05-11 Agouron Pharmaceuticals, Inc. Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
GB0117075D0 (en) * 2000-10-31 2001-09-05 Aventis Pharm Prod Inc Acyl and sulfonyl derivatives of 6, 9-distributed 2-(trans-1, 4-diaminocyclohexyl)-purines and their use as antiproliferative agents
WO2002042303A2 (en) * 2000-10-31 2002-05-30 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
WO2003002565A1 (en) * 2001-06-27 2003-01-09 Cyclacel Limited 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
WO2004069233A1 (ja) * 2003-02-04 2004-08-19 Kabushiki Kaisha Yakult Honsha 乳癌耐性蛋白阻害剤
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
RU2462246C2 (ru) * 2006-03-30 2012-09-27 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней
MX2010003668A (es) * 2007-10-05 2010-07-02 S Bio Pte Ltd Derivados de purina sustituidas con primidina.
CN102241646B (zh) * 2010-05-14 2014-04-09 中国人民解放军军事医学科学院毒物药物研究所 己烯酮类化合物及其医药用途
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
EP3020829B1 (en) 2013-07-12 2021-11-17 Kyoto University Pharmaceutical composition capable of inhibiting abnormal splicing causative of onset or progress of a genetic disease
AU2016206589B2 (en) 2015-01-16 2020-09-10 The General Hospital Corporation Compounds for improving mRNA splicing
CN107903274A (zh) * 2017-12-28 2018-04-13 窦玉玲 一种胺类化合物及其在抗肿瘤药物中的应用
WO2021016263A1 (en) * 2019-07-21 2021-01-28 University Of Virginia Patent Foundation Cysteine binding compositions and methods of use thereof
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
GB9414208D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
CN1066147C (zh) * 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques

Also Published As

Publication number Publication date
ZA991548B (en) 1999-08-26
ATE269332T1 (de) 2004-07-15
NZ506234A (en) 2003-05-30
RU2191777C2 (ru) 2002-10-27
DK1056745T3 (da) 2004-10-25
UA62996C2 (en) 2004-01-15
CA2320448C (en) 2005-02-01
EE04315B1 (et) 2004-06-15
AU3299099A (en) 1999-09-15
KR20010041315A (ko) 2001-05-15
SK12912000A3 (sk) 2001-08-06
PT1056745E (pt) 2004-09-30
AP2000001923A0 (en) 2000-09-30
IL138044A (en) 2006-04-10
OA11480A (en) 2004-05-05
PL344021A1 (en) 2001-09-24
TW541308B (en) 2003-07-11
CN1291983A (zh) 2001-04-18
WO1999043676A3 (en) 1999-10-21
CZ291604B6 (cs) 2003-04-16
CN1128149C (zh) 2003-11-19
HUP0100931A3 (en) 2002-08-28
NO20004281D0 (no) 2000-08-25
EP1056745B1 (en) 2004-06-16
JP2002504553A (ja) 2002-02-12
EE200000501A (et) 2002-02-15
ES2219038T3 (es) 2004-11-16
WO1999043676A2 (en) 1999-09-02
DE69918062D1 (de) 2004-07-22
TR200002482T2 (tr) 2002-10-21
NO20004281L (no) 2000-10-18
KR100568658B1 (ko) 2006-04-07
EP1056745A2 (en) 2000-12-06
SI1056745T1 (en) 2004-12-31
AR019822A1 (es) 2002-03-20
AU748178B2 (en) 2002-05-30
HK1030948A1 (en) 2001-05-25
DE69918062T2 (de) 2005-06-02
CA2320448A1 (en) 1999-09-02
CZ20003106A3 (cs) 2000-12-13
AP1258A (en) 2004-03-15
HUP0100931A2 (hu) 2002-04-29
IL138044A0 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
BR9908325A (pt) 6 9-dissubstituìdo 2-[trans-4(4-aminociclohexil)amino]purinas
BR9909256A (pt) 2- trans- (4-aminociclohexil)amino]purinas 6,9-di-substituìdas
PT96897A (pt) Processo para a preparacao de novos compostos aril-e heteroariletilenicos e de composicoes farmaceuticas que os contem
TR200003429T2 (tr) Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
BR9814124A (pt) Inibidores de aminotiazol de cinases dependentes de ciclina
BR9807814A (pt) Composto, composição farmacêutica, uso de um composto, e, processos de tratamento e para preparação de um composto
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
DE60318030D1 (de) Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
NZ227436A (en) Cell proliferation inhibiting composition comprising a substituted styrene derivative
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
BR9802804A (pt) Compostos benzimidazol, benzoxazol e benzotiazol, processo para sua preparação e composições farmacéuticas contendo os mesmos.
ES2092844T3 (es) Uso de derivados de piridoxal para la preparacion de un medicamento para el tratamiento de cataratas.
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
NO171786C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater
BR0106248A (pt) Inibidores de metaloprotease, processo para a sua preparação e composições farmacêuticas contendo os mesmos
DK677487D0 (da) Indanderivater, deres fremstilling og laegemiddel med indhold deraf
DK661088D0 (da) N-(23-vinblastinoyl)derivater af 1-aminomethylphosphonsyre, fremgangsmaade til deres fremstilling og farmaceutiske midelr indeholdende dem
MX9405111A (es) Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina).
KR950701329A (ko) 벤조티아졸술폰아미드 유도체, 그의 제조법 및 그 용도(Benzothiazolesulfornamide derivative, method for preparing the same, and use thereof)
ES2099180T3 (es) Derivados del benzopirano y procedimientos para su preparacion.
ES2118343T3 (es) Nuevos derivados de 2-(1h)-quinoleinona, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
BR0002265A (pt) Inibidores da metaloprotease, um processo para seu preparo e composições farmacêuticas contendo os mesmos
DK0395527T3 (da) Imidazobenzodiazepiner og deres salte, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og præparater med indhold deraf
PT97885A (pt) Processo para a preparacao de derivados da {(1-aril-2-pirrolidinil)-metil-piperazina e de composicoes farmaceuticas que os contem
ES2192827T3 (es) Derivados de 8h-(2,3-b)-pirrolicin-8-ona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL.: CO7D 473/16; A61K 31/52; A61P 35/00; A61P 25/28.

Ipc: C07D 473/16 (2008.04), A61K 31/52 (2008.04)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B25A Requested transfer of rights approved

Owner name: HMR PHARMA, INC. (US)

Free format text: TRANSFERIDO DE: AVENTIS PHARMACEUTICALS, INC.

B25A Requested transfer of rights approved

Owner name: AVENTIS HOLDINGS INC. (US)

Free format text: TRANSFERIDO DE: HMR PHARMA, INC.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.